# A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Canc

Source: https://onco.cc/trials/nct06284317/  
OnCo record `nct06284317` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial in lung cancer, run by ETOP IBCSG Partners Foundation, now recruiting.

## Summary

A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer. is a phase 3, randomised interventional study registered as NCT06284317 by ETOP IBCSG Partners Foundation, with a registry enrolment figure of 290 participants, started 2025-01-15 and due to reach its primary completion in 2029-10. Interventions recorded: Adjuvant durvalumab. Conditions listed: Non Small Cell Lung Cancer. Primary outcome: Disease-free survival (DFS). Lung eligibility wording from the registry: "* Histologically confirmed NSCLC". Sites: Australia, Austria, Belgium, Estonia, France, Ireland, Italy, Netherlands, Switzerland, United Kingdom. United Kingdom sites listed: 5. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Also known as: ADOPT-lung
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT06284317
- Phase: 3
- Setting: An International, Multicentre, Open-label Randomised Phase III Trial to Evaluate the Benefit of Adding Adjuvant Durvalumab After Neoadjuvant Chemotherapy Plus Durvalumab in Patients With Stage IIB-IIIB (N2) Resectable NSCLC
- Sponsor: ETOP IBCSG Partners Foundation
- Enrolled: 290

## Notes

- UK sites (registry): Barts Health NHS Trust (London); Royal Marsden Hospital (Chelsea) (London); Royal Marsden Hospital (Sutton) (London); Maidstone and Tunbridge Wells NHS Trust (Maidstone); Wythenshawe Hospital, Manchester University NHS Foundation Trust (Manchester).

## Sources

- ClinicalTrials.gov NCT06284317: https://clinicaltrials.gov/study/NCT06284317

## Connected records

- cancers: [Resectable stage I to III non-small-cell lung cancer](https://onco.cc/cancers/resectable-nsclc/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06284317.json